EGFR and non-small cell lung carcinoma: PFS was evaluated in different patient categories: patients with NSCLC and an EGFR mutation who were treatment naïve in one trial [45] or treatment naïve for advanced disease in five trials (Lux-Lung 7 [40], Jo22903 and Jo25567 trial [39], Flaura, [27,29,38]).